EVALUATION OF COMPOUNDS FOR ABUSE POTENTIAL

本合同的目的是获取有关虐待的信息 通过静脉和口服途径的各种药物的潜力 在实验室灵长类动物中施用。具体而言，承包商将 应要求重点生成有关亲属虐待的数据， 通过以下方式自我给药的药物的潜力 评估亲属虐待的先进和敏感的实验室方法 药物类别内和药物类别之间的化合物的易患性。这些数据 至少在一定程度上， 提供有关虐待行为信息的法定义务 药物的潜力为卫生和人类服务部（HHS）。 生成的数据将由食品和药物管理局（FDA）使用 和缉毒局（DEA）提出建议 和决定，分别涉及《公约》 1970年受控物质法（PL 91-513）和国际药物管制法 管制条约（单一公约和精神药物公约）。

The objective of this contract is to obtain information regarding abuse potential of various drugs by intravenous and oral routes of administration in laboratory primates. Specifically the contractor will be asked to focus on generating data pertaining to relative abuse potential of self-administered pharmacological agents by means of sophisticated and sensitive laboratory methods to assess relative abuse liability of compounds both within and between drug classes. These data are needed to fulfill, at least in part, the National Institute on Drug Abuse statutory obligation to generate information concerning abuse potential of drugs for the Department of Health and Human Services (HHS). The data generated will be used by the Food and Drug Administration (FDA) and the Drug Enforcement Administration (DEA) for making recommendations and decisions, respectively, pertaining to scheduling of drugs under the Controlled Substances Act of 1970 (PL 91-513) and international drug control treaties (Single Convention and the Psychotropic Convention).